Affimed spins out discovery capabilities as it approaches the clinic
This article was originally published in Scrip
Executive Summary
Affimed Therapeutics, a German therapeutic antibody company, is to focus all of its activities on the development of its in-house drug candidates. As a result, it has spun out its antibody discovery capabilities into a new company, AbCheck, based in the Czech Republic.